CPhI’s 7th Annual Pharma IPR Conference happening on 7-9 March 2018, Mumbai is a leading platform for Indian pharmaceutical companies to interact with the IP Attorneys and Counsels from across the globe and discuss the recent trends and best practices in the pharma IPR space. Since 2012, Pharma IPR Conference has focused on the importance of Intellectual Property in Pharma syncing it with business objectives of Indian Pharma companies. This three-day conference will provide ample opportunities for business networking with visionary entrepreneurs and industry experts around the world
USA
• Analyzing the impact of New GDUFA II User Fee Structure
• Five years of Inter Partes Review: Effectiveness and Expectations
• Solving a roadblock: Increasing efficiency while limiting the US Litigation Costs
• Updates on ANDA filing and litigation
• Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
• Risk Evaluation and Mitigation Strategies (REMS): Update
• Patent framework for amplified Biosimilars space: Detailed understanding
• Analyzing the impact of New GDUFA II User Fee Structure
• Five years of Inter Partes Review: Effectiveness and Expectations
• Solving a roadblock: Increasing efficiency while limiting the US Litigation Costs
• Updates on ANDA filing and litigation
• Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
• Risk Evaluation and Mitigation Strategies (REMS): Update
• Patent framework for amplified Biosimilars space: Detailed understanding
Europe
• Understanding the Unitary Patent System
• Patent Term Extension and Supplementary Protection Certificate regime (SPCs)
• Implications of IP enforcement on trademarks on Indian exports
• Biosimilars litigation in Europe
• Implications of Brexit on Indian pharma companies
• Understanding the Unitary Patent System
• Patent Term Extension and Supplementary Protection Certificate regime (SPCs)
• Implications of IP enforcement on trademarks on Indian exports
• Biosimilars litigation in Europe
• Implications of Brexit on Indian pharma companies
India Focussed
• Implications of ‘Modified Indian IPR Policy
• PANEL DISCUSSION Reinventing the wheel through value-added generics
• Accelerating Clinical Trials and Pharmaceutical Regulatory Affairs
• Implications of ‘Modified Indian IPR Policy
• PANEL DISCUSSION Reinventing the wheel through value-added generics
• Accelerating Clinical Trials and Pharmaceutical Regulatory Affairs
South Asian Regions Focussed
• Opportunities for India in Indonesian Pharmaceutical Market
• Opportunities for India in Indonesian Pharmaceutical Market
Middle East Focussed
• Understanding the Middle Eastern patent landscape
• Understanding the Middle Eastern patent landscape
Australia Focussed
• Patent protection in Australia & New Zealand
• Patent protection in Australia & New Zealand
Japan Focussed
• The Long Road: Meeting Japanese IP Standards
• The Long Road: Meeting Japanese IP Standards
Who should attend?
> Designations: VP, Head, Senior Managers, Managers, General Manager, Executives/ In-house Counsels
> Departments: IPR, / IP Cell/ Patents/ Legal department
> Industry: Pharmaceuticals, Biopharma
> Designations: VP, Head, Senior Managers, Managers, General Manager, Executives/ In-house Counsels
> Departments: IPR, / IP Cell/ Patents/ Legal department
> Industry: Pharmaceuticals, Biopharma
For more details click here
Share:
0 comments:
Post a Comment